Literature DB >> 8662761

Phosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison with atp-dependent glutamate uptake.

C J Xu1, W E Klunk, J N Kanfer, Q Xiong, G Miller, J W Pettegrew.   

Abstract

ATP-dependent uptake of glutamate into synaptic vesicles has been well documented. Stimulation of glutamate uptake into synaptic vesicles by other high-energy phosphates has not been described. In this paper, we examine the stimulation of phosphocreatine (PCr)-induced glutamate uptake and determine whether this stimulation is secondary to conversion of PCr to ATP. We found the following. 1) PCr stimulates glutamate uptake into synaptic vesicles in the absence of added ATP. 2) At a glutamate concentration of 50 microM, no concentration of added ATP could produce the degree of stimulation seen in the presence of PCr. 3) 0.5 mM iodoacetamide completely inhibits synaptic vesicle creatine kinase activity but does not inhibit PCr-stimulated glutamate uptake. 4) PCr-dependent glutamate uptake, unlike ATP-dependent uptake, is not magnesium- or chloride-dependent. 5) 0.5 mM N-ethylmaleimide, a selective H+-ATPase inhibitor, completely inhibits ATP-dependent glutamate uptake but only slightly inhibits PCr-dependent glutamate uptake. 6) PCr-dependent glutamate uptake is sensitive to valinomycin, a K+/H+ translocator, whereas the ATP-dependent uptake is not. Therefore, it appears that in addition to the well-known ATP-dependent glutamate uptake system, there is a previously unreported PCr-dependent glutamate uptake system in synaptic vesicles. The total glutamate uptake by synaptic vesicles is likely the sum of both ATP- and PCr-dependent glutamate uptake.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662761     DOI: 10.1074/jbc.271.23.13435

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Crystal structure of brain-type creatine kinase at 1.41 A resolution.

Authors:  M Eder; U Schlattner; A Becker; T Wallimann; W Kabsch; K Fritz-Wolf
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Brain metabolic effects of acute nicotine.

Authors:  J W Pettegrew; K Panchalingam; R J McClure; J Levine
Journal:  Neurochem Res       Date:  2001-02       Impact factor: 3.996

3.  A Prophylactic Role for Creatine in Hypoxia?

Authors:  Elisabeth Engl; Mona M Garvert
Journal:  J Neurosci       Date:  2015-06-24       Impact factor: 6.167

4.  Metabolomic Responses to Manganese Dose in SH-SY5Y Human Neuroblastoma Cells.

Authors:  Jolyn Fernandes; Joshua D Chandler; Ken H Liu; Karan Uppal; Li Hao; Xin Hu; Young-Mi Go; Dean P Jones
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

5.  Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency.

Authors:  Gabriela Ullio-Gamboa; Kenea C Udobi; Sophie Dezard; Marla K Perna; Keila N Miles; Narciso Costa; Frédéric Taran; Alain Pruvost; Jean-Pierre Benoit; Matthew R Skelton; Pascale de Lonlay; Aloïse Mabondzo
Journal:  Nanomedicine (Lond)       Date:  2019-04-30       Impact factor: 5.307

6.  Pyruvate and creatine prevent oxidative stress and behavioral alterations caused by phenylalanine administration into hippocampus of rats.

Authors:  Simone Luisa Berti; Guilherme Marmontel Nasi; Cristina Garcia; Fernanda Luz de Castro; Michely Lopes Nunes; Denise Bertin Rojas; Tarsila Barros Moraes; Carlos Severo Dutra-Filho; Clóvis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2011-11-19       Impact factor: 3.584

Review 7.  The role of oxidative stress in Parkinson's disease.

Authors:  Vera Dias; Eunsung Junn; M Maral Mouradian
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

Review 8.  Oral creatine supplementation and skeletal muscle metabolism in physical exercise.

Authors:  José L M Mesa; Jonatan R Ruiz; M Marcela González-Gross; Angel Gutiérrez Sáinz; Manuel J Castillo Garzón
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

9.  Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Lichuan Yang; Kimberly L Ferrante; Steven M Hersch; M Flint Beal; Robert J Ferrante
Journal:  J Neurochem       Date:  2003-06       Impact factor: 5.372

Review 10.  Nutrition and dietary supplements in motor neuron disease.

Authors:  Jeffrey Rosenfeld; Amy Ellis
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-08       Impact factor: 1.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.